VARENICLINE ( DrugBank: Varenicline )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病5
18脊髄小脳変性症(多系統萎縮症を除く。)1

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04403399
(ClinicalTrials.gov)
June 29, 201721/5/2020Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiment 3 - Project #3Parkinson's DiseaseDrug: Varenicline;Drug: PlaceboUniversity of MichiganNULLCompleted45 YearsN/AAll34Phase 2United States
2NCT02933372
(ClinicalTrials.gov)
October 5, 20156/4/2016Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3Parkinson's DiseaseDrug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by InvestigatorUniversity of MichiganNULLCompleted45 YearsN/AAll25Phase 2NULL
3NCT02473562
(ClinicalTrials.gov)
May 201312/6/2015Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's DiseaseVarenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot StudyParkinson's DiseaseDrug: Varenicline;Drug: Placebo (for varenicline)VU University Medical CenterCentre for Human Drug Research, NetherlandsTerminatedN/AN/AAll22Phase 4Netherlands
4EUCTR2012-001530-34-NL
(EUCTR)
09/08/201209/08/2012Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s DiseaseVarenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA) Idiopathic Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Champix
INN or Proposed INN: VARENICLINE
Other descriptive name: VARENICLINE TARTRATE
VU University Medical CenterCenter Human Drug ResearchNot RecruitingFemale: yes
Male: yes
32Phase 3Netherlands
5NCT01341080
(ClinicalTrials.gov)
December 28, 201021/4/2011Varenicline for Gait and Balance Impairment in Parkinson DiseaseVarenicline for the Treatment of Postural and Gait Dysfunction in Parkinson DiseaseParkinson DiseaseDrug: Varenicline;Drug: Sugar pillRush University Medical CenterNULLCompleted40 Years90 YearsAll40Phase 2United States

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000011560
2013/08/3026/08/2013Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration spinocerebellar degeneration (SCD)[High-dose Group]
Oral administration of varenicline

1-7 days 0.5 mg/day
8-14 days 1.0mg/day
15-21 days 1.5mg/day
22-56 days 2.0 mg/day
57-63 days 1.0 mg/day
64-70 days 0.5 mg/day
71-84 days Wash-out period
85-154 days 0.5 mg/day
[Low-dose Group]
Oral administration of varenicline

1-70 days 0.5 mg/day
71-84 days Wash-out period
85-91 days 0.5 mg/day
92-98 days 1.0mg/day
99-105 days 1.5mg/day
106-140 days 2.0 mg/day
141-147 days 1.0 mg/day
148-154 days 0.5 mg/day
Niigata UniversityNULLRecruiting20years-oldNot applicableMale and Female40Phase 1,2Japan